CFB
GPCR icon

Cullen/Frost Bankers’s Structure Therapeutics GPCR Stock Holding History

Cullen/Frost Bankers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386 Hold
8
– – ﹤0.01% 1336
2025
Q4 		$556 Hold
8
– – ﹤0.01% 1342
2025
Q3 		$224 Hold
8
– – ﹤0.01% 1300
2025
Q2 		$166 Hold
8
– – ﹤0.01% 1286
2025
Q1 		$138 Hold
8
– – ﹤0.01% 1271
2024
Q4 		$217 Hold
8
– – ﹤0.01% 1317
2024
Q3 		$351 Hold
8
– – ﹤0.01% 1190
2024
Q2 		$314 Buy
+8
New +$328 ﹤0.01% 1217

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cullen/Frost Bankers's GPCR Position: Q1 2026 in Review

Cullen/Frost Bankers held its Structure Therapeutics (GPCR) position steady in Q1 2026 at 8 shares worth $386. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Cullen/Frost Bankers first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $556 in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Cullen/Frost Bankers held 8 shares of Structure Therapeutics worth $386 as of Q1 2026.
  • Cullen/Frost Bankers left its Structure Therapeutics share count unchanged in Q1 2026.
  • Structure Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q1 2026, its #1336 holding.
  • Cullen/Frost Bankers first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Cullen/Frost Bankers's Structure Therapeutics position peaked at $556 in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.